Development of the Sm14/GLA-SE - schistosomiasis 1 vaccine candidate: An open, not placebo-controlled, standardized dose immunization phase Ib clinical trial 3 targeting healthy young women 4

5 6

2

- Marilia Santini-Oliveira¹, Patrícia Machado Pinto², Tatiane dos Santos², Monica Magno Vilar², 7
- Beatriz Grinsztejn¹, Valdilea Veloso¹, Elan C. Paes-de-Almeida³, Maria A. Z. Amaral⁴, Celso 8
- R. Ramos⁵, Miryam Marroquin-Quelopana⁵, Rhea Coler⁶, Steven Reed⁷, Marcia Ciol⁸, Wilson 9
- Savino^{9,10}, Juçara de Carvalho Parra¹¹ Marília Sirianni dos Santos Almeida², Miriam Tendler^{2*} 10
- 11

15

- ¹Evando Chagas National Institute of Infectology, Fiocruz, Rio de Janeiro, 21045-900, Brazil. 12
- ²Laboratory of Experimental Schistosomiasis, Oswaldo Cruz Institute, Oswaldo Cruz 13 Foundation (Fiocruz), Av. Brasil, nº 4365, Manguinhos, 21045-900, Rio de Janeiro, Brazil. 14
- ³Department of Basic Sciences, Fluminense Federal University, Nova Friburgo, RJ, Brazil 16
- ⁴Program for Development of the *Mata Atlântica Campus*, Fiocruz, Rio de Janeiro, Brazil 17
- ⁵Fenix Biotec Treinamento SS LTDA, São Paulo, Brazil 18
- ⁶Department of Global Health, University of Washington, Seattle, USA 19
- ⁷HDT Bio, Seattle, USA 20
- ⁸Department of Rehabilitation Medicine, School of Medicine, University of Washington, 21 Seattle, USA 22
- 24 ⁹Laboratory on Thymus Research, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil 25
- 26 ¹⁰Brazilian National Institute of Science and Technology on Neuroimmunomodulation, 27 Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil 28
- 29

- ¹¹ René Rachou Institute Fiocruz Minas, Oswaldo Cruz Foundation, Belo Horizonte, Brazil 30
- 31
- *Corresponding author: 32
- 33 E-mail address: mtendler@ioc.fiocruz.br; tendlermiriam@gmail.com (MT)

35 Abstract

We report the successful closure of Phase I clinical trials of the Schistosoma mansoni 14 kDa 36 fatty acid-binding protein (Sm14) + glucopyranosyl lipid A in squalene emulsion (GLA-SE) 37 vaccine candidate against human Schistosomiasis, comprising Phases Ia and Ib. Shown here are 38 the results of Phase Ib, an open, not placebo-controlled, standardized-dose immunization trial, 39 involving 10 healthy 18-49 years old women submitted to the same clinical protocol and the 40 same batch of cGMP Sm14+GLA-SE used in Phase Ia, which was one on men. Fifty µg Sm14 41 protein plus 10 µg GLA-SE per dose were given intramuscularly thrice at 30-day intervals. 42 Participants were assessed clinically, biochemically, and immunologically for up to 120 days. 43

In preambular experiments involving vaccinated pregnant female rabbits, we did not find any 44 toxicological feature either in offspring or mothers, as ascertained by histopathology and 45 biochemical parameters. The vaccine induced adaptive immunity in the animals, as defined by 46 the detection of anti-Sm14 antibodies in the sera. In women, neither serious nor light adverse 47 events were observed. Sm14+GLA-SE vaccination induced high titers of anti-Sm14 serum IgG 48 antibody production. Total anti-IgG serum levels remained high 120 days after the first 49 vaccination dose. Significant increases in Sm14-specific total IgG, IgG1, and IgG3 were 50 observed 30 days after the first vaccination, with specific IgG2 and IgG4 after 60 days. 51 Sm14+GLA-SE vaccination also elicited robust cytokine responses with increased TNFa, 52 IFN γ , and IL-2 profiles in all female vaccinees on days 90 and 120. 53

As in Phase Ia, the Sm14+GLA-SE vaccine was shown to be strongly immunogenic and well tolerated. The completion of Phase I clinical trials performed to the highest standards set by the Good Clinical Research Practice (GCP) standards and pre-clinical data in pregnant rabbits enabled the vaccine candidate to proceed to Phase II clinical trials in endemic areas.

- 59 Study registration ID: NCT01154049 at http://www.clinicaltrials.gov. Brazilian Registry of
- 60 Clinical Trials UTN: U1111-1135-6815
- 61
- 62 Keywords: Vaccine; Schistosomiasis; Phase Ib clinical trial; toxicology; pregnant rabbits;
- 63 Sm14 protein
- 64

66 Introduction

Schistosomiasis is a parasitic disease that affects populations living in areas with very poor 67 sanitary conditions where they get infected through the contact with contaminated water during 68 their daily working, domestic or leisure activities. Children are the main target of the infection 69 that strongly compromises their physical and cognitive development [1,2]. Such a feature turns 70 schistosomiasis, not only into a disease resulting from poverty, but also into a backwardness 71 generator in endemic countries. Schistosomiasis is present in tropical areas of America, 72 Medium East, Asia and Africa, where the impact over public health is catastrophic as a 73 consequence of the size of the territory affected as well as the number of people getting 74 infected. The World Health Organization (WHO) estimates that over 240 million people living 75 in 78 countries are infected and around 800 million live in areas with risk of transmission and 76 infection and are part of global programs directed to the effective control of transmission of 77 schistosomiasis [3]. According to the Ministry of Health, in Brazil, around 1.5 million people 78 live in areas of risk of acquiring the disease [4]. Yet, we still lack a vaccine for protecting the 79 populations from the disease. 80

Presently, the so-called Mass Drug Administration (MDA) program against schistosomiasis is the strategy adopted by WHO in which populations in endemic areas are treated annually with Praziquantel without previous diagnosis. Such strategy actually led to an improvement with regards to the pathology associated to schistosomiasis [5]. However, the world prevalence is still as high as it has always been and the Disability-Adjusted Life Years (DALYs) value , which is an important tool to assess the impact of diseases, has increased [6].

The Sm14 vaccine candidate has been developed at the Oswaldo Cruz Foundation (Fundação Oswaldo Cruz, Fiocruz, Brazil) as a humanitarian vaccine to be used on the population living in areas with risk of infection [7–9].

The Sm14 recombinant protein is currently the basis for a molecular antiparasitic vaccine associated to GLA-SE adjuvant has been developed as an anthelmintic bivalent vaccine, directed against fasciolosis and schistosomiasis. Sm14 is a member of the Fatty Acid Binding Proteins family, originally isolated from *S. mansoni* [10], already identified in most parasite helminths of human and veterinary importance [5–15].

During the experimental phase of Sm14 vaccine development, concentrated in vaccination of 95 outbred animals, it was possible to demonstrate consistent protection against challenge 96 97 infection with cercariae of S. mansoni and significant reduction of adult worm burdens of vaccinated/infected animals evidenced by mean values of adult worm loads and additional 98 measures of the distribution of frequencies of Swiss-Webster mice in sequential worm burdens 99 rates [16–19]. Therefore, one can expect that vaccination with Sm14+GLA-SE in human may 100 lead to the reduction of worm burdens, reducing reinfection rates and diminishing the 101 aggressive inflammatory response that has been observed following interrupted chemotherapy 102 in children living in high-transmission areas [20,21]. 103

The major objective of the Sm14 vaccine project is to promote health access through a safe and immunogenic vaccine capable of blocking the transmission of the disease. This will avoid that populations continue to receive repeated doses of chemotherapeutic drugs during childhood and youth. The design of the vaccine foresees its large-scale use associated to the other control measures already known such as chemotherapy with Praziquantel, sanitation, health education, etc., capable of promoting the control of the disease and mitigating the suffering historically produced by this disease in tropical countries.

The Brazilian National Sanitary Surveillance Agency (Anvisa) approved the start of the Clinical Protocol for Phase Ia Study (CE# 990768/10-8), nonendemic area of Rio de Janeiro, Brazil, with 20 healthy male volunteers, which was completed with success and validated. The validation was done with the use of a Data Bank fed with all records of the study for

calculations and detailed and descriptive statistical analyses of results [22]. In order to comply with the requirements for a similar study in women, Anvisa requested experiments done in pregnant experimental animals. On a second round, and after completion of a requirement for testing the toxicity of the product under investigation, Anvisa approved the Phase Ib Clinical Trial, same Brazilian region as the phase 1a clinical trial, this time with female volunteers. As required by the regulatory agency, the Sm14+GLA-SE formulation was preambularly tested and successfully approved in pregnant rabbits.

The step related to process of vaccination on Phase Ib (with young adult female volunteers) was conducted by the Evandro Chagas National Institute of Infectology (INI/Fiocruz) using the same batches of the Sm14+GLA-SE used on Phase Ia.

The immunogenicity induced by the vaccine Sm14+GLA-SE in women was also approached by means of a platform made available by the Access to Advanced Health Institute (AAHI) (previously Infectious Disease Research Institute IDRI) Seattle, USA to where sera and cells collected in different points of the study from volunteers were shipped. The steps needed to attest safety and immunogenicity of the vaccine and validation of the study were completed and are described in the present work.

131

Materials and Methods

133 Vaccine Antigen and Adjuvant

For the studies carried out in rabbits as well as the clinical trial, the Sm14 vaccine used in the study was produced at the Ludwig Institute for Cancer Research (LICR) and Cornell University, NY, USA under Good Manufacturing Practice conditions (cGMP). Hermetically closed vials, with individual doses (0.55 mL), labelled with product name, Sm 14, lot number (PBR-0057-002), date of manufacture and "*only for investigational use*", were shipped to Brazil under the import authorization from the National Council for Scientific and Technological Development (CNPq) and the Anvisa. Vials were kept at 2-8°C under continuous temperature control from the origin at Fiocruz (Rio de Janeiro) until use, with regular inspections assuring contents remaining liquid and transparent without suspended particles.

The Infectious Diseases Research Institute/ Access to Advanced Health Institute (IDRI/AAHI)
provided the Glucopyranosyl Lipid-A adjuvant in Squalene Emulsion (GLA-SE) vials
containing 0.4 mL, at a concentration of 40 µg/mL, also produced under GMP conditions,
labelled with lot number (Part # 0037-09M001) and manufacturing date. Shipping and storage
followed the same procedures as described above.

The batches of Sm14 and adjuvant were filled finished as single doses and mixed at the moment of immunizations.

To formulate the vaccine antigen dose at the time of administration, 0.4 mL of a 200µg/mL 151 Sm14 suspension were aspirated using a 1 mL sterile syringe. Subsequently, the volume of the 152 syringe was injected into the vial containing the GLA-SE adjuvant, obtaining a total volume of 153 0.8 ml mixture. After mixing by inverting the vial, 0.5 mL containing 50µg of Sm14 protein 154 and 10µg adjuvant was administered by intra-muscular route to both animals and women 155 volunteers. The dose used in these studies were based on a clinical protocol approved by 156 Anvisa for the Phase Ia study in male volunteers [22]. The two components of the vaccine 157 candidate, kept in separate vials, were monitored by Pharmaceutical Product Development 158 (PPD) [23]. Samples were sent to PPD for control every three months in accordance with 159 applicable standard operating procedures and the US Food and Drug Administration (FDA) 160 regulations. Stability of the Sm14 GMP lot was followed by PPD and updated "Certificate of 161 Analysis" issued. 162

Pre-clinical experiments on safety and immunogenicity of pregnant 163 rabbits and respective off springs, following Sm14 vaccination in 164 the mothers 165

The study in pregnant rabbits was conducted in accordance with the protocol provided by 166 Anvisa. It was reviewed and approved by the Ethics Committee on Animal Research of Fiocruz 167 (CEUA/Fiocruz) n° L0063/08 – LW 19/2013. 168

The reproductive toxicity tests were performed with the same vaccine lot further used in Phase 169 I Clinical Trials, which was produced under current good manufacturing practice (cGMP) 170 conditions by LICR/Cornell University, NY, USA. Vials containing individual doses (0.55 mL, 171 200 µg/mL) were labelled with the product name (Sm14) and lot number (PBR-0057-002). 172 Vials were kept at +2-8°C under continuous temperature control until use, with regular 173 inspections to assure that the contents remained liquid and transparent without suspended 174 particles. 175

176 Twenty-four NZW pregnant rabbits, with the same age and weight at the beginning of the experiment, were divided into two groups just after mating: one group comprising 12 rabbits 177 immunized with three equal doses of 50 µg Sm14+10 µg GLA-SE/dose, with a 7-day interval 178 between doses; and the control group, comprising 12 rabbits injected with PBS, same days 179 intramuscularly. Injections of 0.5 mL/dose for each dose schedule were at the external middle 180 181 third of the right and left thigh alternately, and administered on days 0 (day 9 of pregnancy), 7 (day 16 of pregnancy), and 14 (day 23 of pregnancy). The pregnancy period of these animals is 182 approximately 30 days. Necropsy and anatomopathological evaluations were performed on day 183 29 of pregnancy. 184

All animals had the inoculation area shaved and marked before each immunizing dose, to 185 assess further possible local reactions that might include ervthema and edema; both being 186 scored according to standard protocols [24]. Daily clinical evaluation of each animal was 187

performed and duly recorded in the individual data chart by a veterinarian. Parameters such as occurrence of abortion, stress level, appetite, manure, and skin/local reactions at inoculations sites, were evaluated and measured. Body weight was determined at the beginning and at the end of the study. Food and water consumption was recorded every day individually.

Biochemical and blood cell evaluation was done following current laboratory practices and included liver, renal and pancreatic functions, as well as red and white blood cell countings and coagulation parameters.

All animals were anesthetized with thiopental sodium and euthanized by exsanguination. Detailed anatomopathological analyses of all organs were carried out following euthanasia. All animals were subjected to a macroscopic inspection of the organs and cavities. Samples of organs were collected in buffered 10% formalin for later microscopic analysis. The ovaries, uteri, and fetuses were collected and fixed for further analysis, such as number, size, weight, *corpora lutea*, placenta and living fetuses. Paraffin-embedded tissue sections were stained with hematoxylin and eosin (H&E) and examined under a light microscope [25].

Serum samples were collected from all rabbits before the start of pregnancy and on the date of 202 203 euthanasia. The total anti-Sm14 IgG antibody titers in rabbit sera samples were determined by ELISA [26] in accordance with previously described procedures [27]. Briefly, the wells were 204 coated overnight at 4°C with 100 µL/well of Sm14 protein solution at 4 µg/mL in carbonate 205 buffer 0.1 M pH 9.6, blocked for 1h at 37°C, and then serum samples were added in two-fold 206 serial dilution from 1/100 up to 1/1600. After washing, peroxidase conjugated goat anti-rabbit 207 total IgG specific to the gamma chain (Santa Cruz Biotechnology, USA) was added to each 208 well, and the plates were incubated for 1h at 37°C. Wells were washed and the reaction was 209 developed by the addition of TMB substrate (Sigma-Aldrich, T0440) for 15 min at room 210 temperature in the dark followed by the addition of Stop reagent (Sigma-Aldrich S5814); 211 subsequently, the OD at 450 nm was measured using a BIORAD device, Model 680. 212

All statistical analyses were carried out by using GraphPad Prism version 4.0 software. All analyses were conducted by applying the two-tailed test, with *p*-values below 0.05 considered to be significant.

216

217 Phase Ib clinical trial in healthy women

The methodology used to conduct the Sm14+GLA-SE candidate vaccine Phase 1b clinical trial in women was essentially the same described by Santini-Oliveira et al. [22] for Phase 1a with healthy male adults (CE # 990768/10-8 - CAAE 0018.0.009.000-10). The protocol for the Phase Ib trial was approved by Anvisa (CE# 0577594139) and by the Evandro Chagas Review Council of the National Institute of Infectious Diseases (INI), Fiocruz (CAAE 09627212.4.0000-5262). In addition, tests were monitored by TECHTRIALS, an independent research company, and data was deposited into a Data Bank [28] under the code NCT01154049.

Twenty healthy female volunteers from a non-endemic area of Brazil (City of Rio de Janeiro) 225 were enrolled and registered under numbers from #1 to #20. Among them, 10 were selected 226 and went up to the end of the study. Inclusion criteria comprised negative pregnancy test, 227 availability during the whole duration of the trial, no evidence of any acute infection, no 228 previous or ongoing serious chronic disease, normal findings for organ functions as 229 demonstrated by laboratory tests and physical examination of the cardio-respiratory and 230 brain/neurological, abdominal organs, skin, and lymphatic system. Exclusion criteria included 231 pregnancy/breast feeding, abnormal hematology or blood chemistry counting or data, any kind 232 of ongoing infection, including infection by the human immunodeficiency virus (HIV), any 233 chronic disease, alcohol/drug abuse or history of medication or vaccination in the preceding 234 month. After clinical screening, the 10 participants aging 26-48 years (mean=36.3, sd=6.8) 235 were selected for the trial, and their demographic characteristics are depicted in S1 Table. 236

Full physical examens and laboratory tests were done on baseline and days 0, 7, 30, 37, 60, 67, 237 90 and 120 (Supplemental figure 1). Participants were monitored at the site up to one hour after 238 vaccination and followed-up by phone 20-28 hours afterwards. According to Santini-Oliveira 239 [22], all adverse episodes were evaluated in compliance with the International Centers for 240 Tropical Disease Research network (ICTDR), and according to the degree of severity as 241 follows: Level 1 (tolerable with mild discomfort and not interfering with regular activities); 242 Level 2 (discomfort with the impairment of regular activities but not requiring any specific 243 medical assistance, or treatment); Level 3 (requiring discharge of regular activities and medical 244 intervention) and Level 4 (life threatening). The laboratory at the Evandro Chagas National 245 Institute of Infectology (INI) is certified by the College of American Pathologists (CAP, EUA) 246 and laboratory tests were evaluated based on the INI Standard Values Chart. The study 247 followed FDA regulations [29]. 248

Samples of peripheral blood mononuclear cells (PBMCs) and of sera were collected from all 249 subjects on baseline and days 0, 30, 60, 90 and 120. Immediately after collection, PBMCs were 250 separated by centrifugation at room temperature in Ficoll-Paque Plus (GE Healthcare, USA) 251 and mixed with Fetal Bovine Serum (FBS) (Gibco Life Technologies, USA) and 10% DMSO. 252 Cells were subsequently transferred to 2 mL cryovials and frozen down to -80°C in a 253 NALGENE TM Crvo 1°C freezing container (Nalgene, USA) overnight. On the following day 254 vials were transferred to liquid nitrogen and later dry shipped to the Infectious Disease 255 Research Institute (IDRI, Seattle, USA) where they were stored in liquid nitrogen until use. 256

Sera were also stored in Brazil at -80°C and transferred in dry ice to IDRI for analysis. At IDRI, sera were stored at -80°C, till experiments were performed. The immunogenicity analyses included isotype check of anti-Sm14 antibodies and cell-mediated responses specifically induced after vaccination with Sm14+GLA-SE. It also included detection and quantification of intracellular cytokines after stimulation of PBMCs with purified rSm14.

Immune cell responses were measured using the PBMC Luminex Kit for T cell cytokines (Milliplex ®MAP) [22]. Isotyping and the correlation between the development and the size of humoral response measured in terms of IgG against the Sm14 protein were done by enzymelinked immunosorbent assay ELISA [22,26].

Descriptive analysis using IBM SPSS v20 statistical package was performed for all variables. 266 Boxplots for all follow-ups assessed whether observations were outside the limits specified for 267 specific laboratory tests. Proportions of adverse events and 95% confidence intervals were 268 269 calculated using Clopper-Pearson method [30]. For toxicity grading scales, we used limit values based on published information when available, which included clinical experience and 270 reviewed vaccine clinical trials on healthy subjects. Toxicity grading scales were based on the 271 272 local laboratory reference values when those were defined. Statistical analyses of immunogenicity data were performed using analysis of variance, followed by Tukey's test for 273 multiple comparisons. 274

The statistical analysis was done based on the evaluation of local and systemic reactogenicity observed in the first 36 hours after each dose of the vaccine. Results of chemical and hematological exams were compared to reference values in accordance with the Richet Laboratory (LR) criteria and ICTDR, including levels of toxicity as defined by FDA [29].

280

- 282
- 283

285 **Results**

Sm14 vaccine candidate does not induce any toxicological effect in pregnant rabbits

The body weights and structures of the analyzed organs in all pregnant rabbits, irrespective of 288 being or not vaccinated were within normal limits, according to established criteria [31]. 289 Macroscopic analysis of organs and cavities revealed results consistent with the usual aspects 290 for normal pregnant rabbits [32]. The ovaries of all 24 animals were consistent with normal 291 292 appearance. All analyzed uteri were comparable with a normal pregnant uterus for outbred rabbits according to established criteria [33]. The microscopic results showed that the ovaries 293 of all 24 pregnant rabbits had follicles at different stages of development in the cortical region, 294 usual interstitial stromal glands and containing varying numbers of corpora lutea (Figure 1). 295 There was no statistically significant difference for any of the parameters assessed in this study 296 297 between vaccinated and control animals. Table 1 shows that the duration of pregnancy, the number of implantation sites in the uterus, and the number and viability of pups guarantee the 298 absence of maternal and embryo-fetal toxicity in pregnant rabbits vaccinated with Sm14+GLA-299 300 SE. The results were also consistent with the morphological and physiological aspects reported for farmed NZW rabbits [31-33]. 301

308

Fig 1. Normal macroscopic and microscopic views of an ovary from a Sm14/GLA-SE vaccinated pregnant rabbit. Panel A depicts the normal macroscopic pattern of the ovary, showing multinodular outer surface and brownish with marked vessels. Panel B shows microscopic view with follicles in various stages of development in the cortical region (within the black circles). Corpora lutea (CL) can be seen in panel C whereas a higher magnification of a follicle can be seen in Panel D. Sections were stained with Hematoxylin-eosin. Scale magnification with the objectives for 40x (in panel B), 100x (in panel C) and 200x in panel D).

Table 1. Sm14 vaccination does not induce changes in pregnancy parameters

Experimental Groups	Number of fetuses	Size of fetuses (cm)	Weight of Fetuses (g)	Number of corpora lutea	Number of Placentae	Number of Live Fetuses	Percentage of Live Male Fetuses/Litter
					(deployments)		
Sm14+GLA-SE	6.60 ± 2.78	6.85 ± 2.40	23.43 ± 11.32	6.33 ± 3.14	7.58 ± 3.02	83	56.25 ± 30.24
PBS Control	7.00 ± 3.24	7.10 ± 0.83	21.58 ± 7.32	7.25 ± 2.89	8.42 ± 2.99	84	55.60 ± 34.91

312 Data are presented as the mean \pm standard deviation. The parameters were evaluated by Student's *t*-test to compare the mean values of groups. In all cases, differences were considered statistically significant for p values of < 0.05. No differences were found.

The skin and subcutaneous tissue were removed from the injection sites of the immunized 314 animals. The results of the individual tests showed no significant histopathological alterations in 315 the skin at the immunization site. In the anatomopathological evaluation of the organs, it was 316 observed that all groups, including the control group, had small and scarce foci of calcification in 317 5% of the cortical and medullary tubules of the kidneys. 318 Lastly, ELISA was used to analyze sera collected from the animals after the final injection and 319 showed considerably high production of the anti-Sm14 antibody in the sera of vaccinated versus 320 non-vaccinated PBS-treated pregnant rabbits. Anti-Sm14 antibody levels (evaluated by optical 321 322 density) were clearly high in the vaccinated group as compared to controls (Figure 2). 323

Figure 2. Total anti-Sm14 IgG antibody titers, determined by ELISA, of all rabbit serum samples from the two
 groups in the reproductive toxicity study. OD: optical density.

326

Sm14 vaccine candidate does not induce any major adverse effects (AEs) in healthy women

The certification of Sm14+GLA-SE vaccine safety in this preclinical study paved the way for the 329 phase Ib clinical trial of the vaccine in young adult non-pregnant women. The candidate vaccine 330 Sm14+GLA-SE was shown to be safe with no serious adverse events as observed in the participants after 331 any of three doses. No local reactions at the site of the injection occurred, except for local pain which 332 333 affected 9 out of 10 women after the first dose, 5 out of 9 after the second, and 4 out of 10 after the third (all lasting less than 24 hours after injection). Only one subject reported involuntary muscle contractions 334 lasting 5 minutes near the site of infection after the first dose. Table 2 shows the adverse events associated 335 336 with vaccination of the healthy female volunteers in the Phase Ib.

338	Table 2.
339	Adverse events related to the injection of vaccine: reactions at the site of the injection and
340	systemic reactions during the first 36 hours after the administration of the vaccine
341	

		Proportion (95% Confidence Intervall)		
Type of Adverse Effect	First Dose	Second Dose	Third Dose	
	(Day 1)	(Day 31)	(Day 61)	
Number of participants	10	10*	10	
Serious adverse effects	0.000	0.000	0.000	
	(0.000, 0.308)	(0.000, 0.308)	(0.000, 0.308)	
Reactions in the of the injection				
Reaction to touch	0.000	0.000	0.000	
	(0.000, 0.308)	(0.000, 0.308)	(0.000, 0.308)	
Erythema	0.000	0.000	0.000	
	(0.000, 0.308)	(0.000, 0.308)	(0.000, 0.308)	
Induration	0.000	0.000	0.000	
	(0.000, 0.308)	(0.000, 0.308)	(0.000, 0.308)	
Edema	0.000	0.000	0.000	
	(0.000, 0.308)	(0.000, 0.308)	(0.000, 0.308)	
Local pain	0.900	0.556	0.400	
	(0.555, 0.997)	(0.212, 0.863)	(0.122, 0.738)	
Involuntary muscle contractions, light	0.100 (0.003, 0.445)	0.000 (0.000, 0.308)	0.000 (0.000, 0.308)	

*One missing value for local pain 342

With regards to systemic adverse events, two participants had fever at D7, and two others had 343 light local hyperemia and headache at D37, probably related to the vaccine. Physical exams on all 344 days (baseline, 0, 7, 30, 37, 60, 67, 90, and 120) showed no clinical alterations or abnormalities. 345 Laboratory exams did not show alterations that could be classified as toxicity according to the 346 ICTDR criteria, except for ALT and GGT, with few participants showing elevated values within 347 toxicity levels. However, these participants also had elevated values prior to the vaccination (at 348 baseline), and since they had no other abnormal laboratory findings or clinical symptoms, they 349 were considered as most probably not related to the vaccine. All other single instances of values 350

outside of the normal range were evaluated and, given that no abnormal laboratory findings or clinical symptoms were observed, they were all considered as non-clinically significant (that is, most probably not related to the vaccine). These data show that the vaccine produced very few adverse effects and all the observed events were local and mild (Tables 3 and 4).

356

357 358

359

Table 3.	
Secondary adverse events* in Sm14 vaccinated young	5

Day of Exam	Symptoms	Relationship to the Sm14 Vaccine
D0**	Patient #10: Vomit, light. Patient #13: Sleepiness, light.	Not related to the vaccine.
D7	Patient #7: Fever. Patient #8: Fever.	Fever in patients #7 and #8: probably related to vaccine
D30	Patient #12: Gallstones, light	Not related to the vaccine.
D37	Patient #10: Local hyperemia light. Patient #13: Light hepatic steatosis; light headache.	Patient #10 probably related to vaccine #13 possibly related to vaccine.
D60	Patient #3: Cold. Patient #10: Flu, light. Patient #14: Urinary tract infection,	Not related to the vaccine
D67	Patient #1: Cervicalgia, light. Patient #5: Pain in right heel, light.	Not related to the vaccine
D90	Patient #7: Vaginal discharge, light. Patient #13: Flu, light.	Not related to the vaccine
D120	Patient #2: Light elevation of GGT. Patient #3: Moderate eosinophilia. Patient #10: Light Headache.	Not related to the vaccine

360 * New symptoms since last examen.

361 ** Previous exam was at Baseline. D0 is the day of the first dose.

362 Numbers preceded by # correspond to participant's code numbers.

Table 4. 364 Summary of laboratory tests and physical exams in Sm14 vaccinated young adult women 365

Type of Test	Findings * (#: Participant study number; RV= Reference Values)	Toxicity Evaluation		
Hematologic tests				
MCV (fl)	#3: slightly below lower limit at D120	No toxicity observed.		
Total leucocytes (/µL)	#2 and #10: above upper limit for LRRV, but below ICTDR at baseline.#13: above upper limit for LR RV, but below ICTDR at D90 and D120.	No toxicity observed.		
Eosinophil (%)	 #2: above upper limit for LR RV at D37, D67, D120 #3: above upper limit for LR RV at B, D7, D67, D90, D120 #7: above upper limit for LR RV at, B, D7, D90 #12: above upper limit for LR RV at, D37, D67, D90 	ICTDR has no recommendations for toxicity. Elevated values on all follow-ups were probably not related to vaccine.		
Neutrophil (%)	Observations within LR RV for all follow-ups.	No toxicity observed.		
Segmented neutrophil (%)	#2: slightly above LR RV at D90 (NCS) #3: below LR RV at B	ICTDR has no recommendations for toxicity Elevated values D90 was probably not related to vaccine.		
Lymphocytes (%)	A few values were below the lower limit of VR LR.	ICTDR has no recommendations for toxicity. No toxicity observed.		
Atypical lymphocyte	None observed	No toxicity observed.		
Monocytes (%)	#1: value above the LR RV at D120 (NCS)#12: value above the LR VR at D37 (NCS)	ICTDR has no recommendations for toxicity.		
Hemoglobin (g/dL)	Few values were observed below the VR LR.	No toxicity observed		
Platelets (/µL)	#14: above LR RV at D37 (NCS)	No toxicity observed		
Red blood cells (M/µL)	Few values observed below the LR RV.	No toxicity observed		
Hematocrit (%)	Few values observed below the LR RV.	No toxicity observed.		

Basophil (%), Myelocyte (%), Metamyelocyte (%)	None found in all participants during the entire study.	
Activated partial thromboplastin time PTT (sec)	Few values below the LR RV.	No toxicity observed.
Prothrombin time (seg)	No values outside LR RV.	No toxicity observed
Prothrombin ratio (%)	#2: Above LR RV at D7 (NCS) #14: Above LR RV at B (NCS), D7 (NCS), D120 (NCS).	No toxicity observed according to medical chart.
International Normalized Ratio (RNI)	No values were above the LR RV.	No toxicity observed.

Blood Chemistry

Sodium (mmol/L)	No values were above the LR RV.	No toxicity observed.
Potassium (mmol/L)	#1: Above LR RV at D37 (NCS), D67 (G1). #10: Above LR RV at D37 (NCS).	#1 did not show other symptoms or other abnormal laboratory findings and was considered no toxicity, according to medical chart.

Liver function

Total Bilirubin (mg/dL)	No values were above the LR RV.	No toxicity observed.
Direct Bilirubin	#1: Value above LR RV at Baseline –	No toxicity observed.
(mg/dL)	not attributable to vaccine.	
Indirect Bilirubin (mg/dL)	No values were above the LR RV.	No toxicity observed
Alkaline Phosphatase (U/L)	#13: Above LR RV at all follow-ups, including baseline.	High values for #13 probably not be due to vaccine (was high at baseline). No toxicity observed according to medical chart.
AST (U/L)	#12: Above LR RV at D90 (NCS)	#12 Not clinically significant according to medical chart. No toxicity observed.
ALT (U/L)	#12: Above LR RV at D90 (G1 – NCS) #13: Above LR RV at D7, D67, D90 (NCS for all).	#12 Above ICTDR threshold for grade 1 toxicity, but not clinically significant according to medical chart. No other toxicity observed.

medRxiv preprint doi: https://doi.org/10.1101/2022.08.17.22278904; this version posted August 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a	CC BV AC	International	liconco
It is made available under a	CC-DT 4.0	J milemational	license.

Abnormalities	None observed.	No toxicity observed.
	Abdomen physical exam	
Calcitonin (pg/mL)	No values were above the LR RV	No toxicity observed.
	Other blood test	_
Urea (mg/dl)	No values were above the LR RV.	No toxicity observed.
Creatinin (mg/dL)	#13: Above LR RV at D67 e D120, but below ICTDR toxicity.	No toxicity observed.
	Kidney function (serum tests)	
	D67(G2), D90(G2), D120(G2)	
	D67(G1), D90(G2), D120(G2) #13. B (G2) D7(G2) D37(G2)	most likely not to the vaccine
	#12: B (G1), D7(G2), D37(G2),	through the follow-up were
GGT (U/L)	#2: B, D/, D3/, D6/, D90, D120 (G1 in all but not D7)	and their elevated values
		An unce participants had

367 G1 = Toxicity Grade 1, G2 = Toxicity Grade 2;

368 Numbers preceded by # correspond to participant's code numbers.

369

366

370

371 Sm14 does induce adaptive immune responses in healthy women

As occurred with male subjects on Phase IA [22], the immune response of females vaccinated 372 with the Sm14+GLA-SE was characterized by high levels of anti-Sm14 IgG, mainly of the IgG₁ 373 isotype. Responses were augmented after the second dose. Ninety percent of vaccinated subjects 374 developed higher specific total IgG antibody titres 90 days post vaccination and theses titres 375 remained as high up to 120 days. Compared to baseline, total specific IgG, as well as IgG₁ and 376 IgG₃, increases were statistically significant from day-60 (Figure 3). The levels of specific IgG₂ 377 and IgG₄ increased after the second dose and achieved statistical significance from day-90 up to 378 day-120. Also, neither general nor specific IgE increases were detected at any time. 379

The Sm14+GLA-SE vaccination elicited robust cytokine responses. Cytokine profiles show
increased TNFα, IFNγ, and IL-2 in vaccinated individuals on days 90 and 120. Analysis results
indicated overall comparable responses among male and female cohorts [22] (Fig 3).
Figure 3. Levels of anti-Sm14 antibody classes and cytokine production stimulated by vaccination. (A) ELISA
antibody results (B) Percentage of CD4⁺ T cells expressing combinations of IFNγ, TNF_a and IL-2 production in CD4⁺
T cells on days 0, 30, 90 and 120. *p*-values for comparison was performed for vaccinated group to baseline (Day 0).

387 388

389 **Discussion**

**p*-values at the 0.05 significance level.

Safety is the most important attribute of a vaccine designed for large-scale use in endemic populations. The studies described herein were the basis for legal authorization to start clinical trials for the Sm14 vaccine in Brazil. The preparation was evaluated according to WHO recommendations and guidelines in multiple-dose and reproductive studies that provided preclinical data ensuring the safety of the vaccine formulation [34].

For obtaining authorization from the Brazilian health authorities to initiate phase I clinical trials of 395 Sm14+GLA-SE anti-schistosomiasis vaccine. Anvisa has approved the study to be performed in 396 healthy men living in non-endemic areas for schistosomiasis but did impose a restriction to the 397 engagement of women of childbearing age. A preambular reproductive toxicity test was required 398 399 in pregnant rabbits, to ensure vaccine safety for this population group. The variations observed in laboratory blood tests did not indicate a significant effect on the health of the animals. Coherently, 400 401 the animals did not show relevant clinical alterations associated with the study and no macroscopic or histopathological alterations were observed that represented clinical significance. 402 Most of the analysed parameters were within the normal range of variation, indicating that the 403 vaccine was safe and well tolerated at either dose level, in addition to providing clear humoral 404 immune response. 405

These data provided the green light to the Sm14 vaccine clinical test in women at childbearing age, to evaluate the clinical steps of the safety and immunologic evaluation of the Sm14+GLA-SE anti-schistosomiasis candidate vaccine in healthy volunteer women (clinical trial Phase Ib).

Results obtained in women have confirmed the pattern of responses of Phase Ia with male adults [22]. Our immunological analysis revealed that Sm14 induced a broad spectrum of immune responses stimulating both Th1 and Th2 cytokines However, there was neither a specific nor a general IgE increase, an immunoglobulin associated to the pathogenesis of immediate hypersensitivity reactions because of its ability to bind specifically to high affinity receptors on mast cells or basophils by the alpha chain of the FC receptor.

415

416 Conclusion and perspectives

Preclinical assays on pregnant rabbits revealed that the candidate anti-schistosomiasis rSm14-GLA-SE vaccine test resulted in no changes concerning the reproductive status and well as other pregnancy parameters. Moreover, Phase Ib clinical trial applied to healthy young adult women confirmed that no serious adverse events were observed after three doses of 50 μ g Sm14 + 10 μ g GLA-SE in 10 women from a schistosomiasis non-endemic area, administered three times with 30-day interval.

Based on data generated from the clinical studies done so far, severe toxicity (Grade 3 or 4), either local and/or systemic, is not expected to occur. The administration of the investigational product is anticipated to be well tolerated. So, local reactions (such as pain at the site of injection, erythema, induration, edema, or pruritus) may occur but are usually mild, self-limited, and subside without treatment.

As observed on this trial, adaptive cell-mediated and humoral immune responses (IgG and isotypes, but not IgE), along with many previous preclinical results, strongly support Sm14 as an

effective vaccine against *S. mansoni* infection. Possibly, it will also be useful against infections
caused by other species of *Schistosoma*.

Clinical studies are a prerequisite for licensing drugs and immunobiologicals by regulatory 432 agencies in most countries. In this way, they are a constituent part of the process of research and 433 development of supplies for human health. The Sm14+GLA-SE vaccine is at an advanced stage of 434 development, after successfully passing through pre-clinical stages and Clinical phases Ia and Ib, 435 is presently in phase II, clinical trial in the Senegal River Delta region, in African endemic sites 436 437 for both S. mansoni and S. haemathobium. It is believed that the development of a safe, effective, and humanitarian vaccine will change the epidemiological profile of this disease, thus freeing 438 countries such as Brazil and much of the African continent from one of the major stigmas of 439 underdevelopment, which are parasitic diseases and particularly schistosomiasis. 440

441

442 Acknowledgements

443 We thank the researchers and nurses from the staff of the INI/Fiocruz, for conducting the study. Lots of thanks to Tom Vedvick of the Infectious Disease Research Institute, for most valuable 444 advices and support for the formulation of Sm14with GLA, to Andrew J. G. Simpson, scientific 445 director of the company Orygen Biotecnologia S.A, that funded part of clinical trials for the 446 Sm14-GLA-SE Schistosomiasis Vaccine Development Project, to Donald De Roo, from LICR for 447 technical support for setting up the Fill Finish procedures at Florida Biologix and Quality Control 448 Panel at PPD Inc., to Carlos Henrique Henrique of Ourofino Animal Health Inc. for support at all 449 levels with operational steps and pre-clinical animal tests and finally to Jorge Bermudez, former 450 Vice President of Innovation and Production of Fiocruz and to PHI/WHO(World Health 451 Organization) for strategic support. 452

- 454 **Funding:** This study was funded by FINEP (*Financiadora de Estudos e Projetos* Federal
- 455 Governmental Funding Agency); FAPERJ (Funding Agency from Rio de Janeiro State);
- 456 IOC/FIOCRUZ (Oswaldo Cruz Institute/Oswaldo Cruz Foundation, Brazilian Health Ministry),
- 457 CNPq (Brazilian Ministry of Science Technology & Innovation), OUROFINO Saúde Animal, and
- 458 Orygen Biotecnologia.

460 **References**

- Poole H, Terlouw DJ, Naunje A, Mzembe K, Stanton M, Betson M, et al. Schistosomiasis in pre-school-age children and their mothers in Chikhwawa district, Malawi with notes on characterization of schistosomes and snails. Parasit Vectors. 2014 Apr 1;7:153.
- 465 2. Osakunor DNM, Woolhouse MEJ, Mutapi F. Paediatric schistosomiasis: What we know and
 466 what we need to know. PLoS Negl Trop Dis. 2018 Feb 8;12(2):e0006144.
- 467 3. World Health Organization. WHO guideline on control and elimination of human
 468 schistosomiasis [Internet]. Geneva: World Health Organization; 2022 [cited 2022 May 18].
 469 118 p. Available from: https://apps.who.int/iris/handle/10665/351856
- 470 4. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância
 471 Epidemiológica. Vigilância da Esquistossomose Mansoni : diretrizes técnicas. 4th ed. Brasília:
 472 Ministério da Saúde; 2014. 144 p.
- 473 5. World Health Organization, editor. Preventive chemotherapy in human helminthiasis:
 474 coordinated use of anthelminthic drugs in control interventions; a manual for health
 475 professionals and programme managers. Geneva: World Health Organization; 2006. 62 p.
- 476 6. Bergquist NR. Schistosomiasis: from risk assessment to control. Trends in Parasitology. 2002
 477 Jul 1;18(7):309–14.
- Tendler M, Almeida MS, Delbem ACB, Silvaii JoseFD, Savino W, Garrattf RC, et al. A
 Schistosoma mansoni fatty acid-binding protein, Sml4, is the potential basis of a dual-purpose
 anti-helminth vaccine. Proc Natl Acad Sci USA. 1996;5.
- Tendler M, Almeida M, Simpson A. Development of the Brazilian Anti Schistosomiasis
 Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant.
 Front Immunol. 2015 May 12;6:218.
- 484
 9. Tendler M, Almeida MS, Vilar MM, Pinto PM, Limaverde-Sousa G. Current Status of the
 485 Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the
 486 First Anti-Parasitic Human(itarian) Vaccine. Tropical Medicine and Infectious Disease. 2018
 487 Dec;3(4):121.
- 488 10. Moser D, Tendler M, Griffiths G, Klinkert MQ. A 14-kDa Schistosoma mansoni polypeptide
 489 is homologous to a gene family of fatty acid binding proteins. J Biol Chem. 1991 May
 490 5;266(13):8447–54.
- 491 11. Bergquist NR, Colley DG. Schistosomiasis Vaccine:Research to Development. Parasitology
 492 Today. 1998 Mar 1;14(3):99–104.
- 493 12. Al-Sherbiny M, Osman A, Barakat R, El Morshedy H, Bergquist R, Olds R. In vitro cellular
 494 and humoral responses to Schistosoma mansoni vaccine candidate antigens. Acta Tropica.
 495 2003 Oct 1;88(2):117–30.
- 496 13. Tendler M, Simpson AJG. The biotechnology-value chain: Development of Sm14 as a
 497 schistosomiasis vaccine. Acta Tropica. 2008 Nov 1;108(2):263–6.

- 498 14. Molehin AJ, Rojo JU, Siddiqui SZ, Gray SA, Carter D, Siddiqui AA. Development of a
 499 schistosomiasis vaccine. Expert Review of Vaccines. 2016 May 3;15(5):619–27.
- 15. Hotez PJ, Bottazzi ME, Bethony J, Diemert DD. Advancing the Development of a Human
 Schistosomiasis Vaccine. Trends in Parasitology. 2019 Feb 1;35(2):104–8.
- Tendler M, Pinto RM, Côrtes M, Gebara G. Schistosoma mansoni: comparative evaluation of
 different routes of experimental infection. Rev Inst Med Trop Sao Paulo. 1985 Jun;27(3):111–
 4.
- Tendler M, Pinto RM, Oliveira Lima A, Gebara G, Katz N. Schistosoma mansoni: vaccination
 with adult worm antigens. Int J Parasitol. 1986 Aug;16(4):347–52.
- 18. Tendler M, Pinto RM, Lima A de O, Savino W, Katz N. Vaccination in murine
 schistosomiasis with adult worm-derived antigens: variables influencing protection in outbred
 mice. Int J Parasitol. 1991 Jun;21(3):299–306.
- Tendler M, Almeida MS, Pinto RM, Noronha D, Katz N. Schistosoma mansoni-New Zealand
 rabbit model: resistance induced by infection followed by active immunization with protective
 antigens. J Parasitol. 1991 Feb;77(1):138–41.
- 20. Olveda RM, Daniel BL, Ramirez BDL, Aligui GDL, Acosta LP, Fevidal P, et al.
 Schistosomiasis Japonica in the Philippines: The Long-Term Impact of Population-Based
 Chemotherapy on Infection, Transmission, and Morbidity. The Journal of Infectious Diseases.
 1996 Jul 1;174(1):163–72.
- 21. Reimert CM, Tukahebwa EM, Kabatereine NB, Dunne DW, Vennervald BJ. Assessment of
 Schistosoma mansoni induced intestinal inflammation by means of eosinophil cationic protein,
 eosinophil protein X and myeloperoxidase before and after treatment with praziquantel. Acta
 Tropica. 2008 Mar 1;105(3):253–9.
- Santini-Oliveira M, Coler RN, Parra J, Veloso V, Jayashankar L, Pinto PM, et al.
 Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults. Vaccine. 2016 Jan 20;34(4):586–94.
- 524 23. Global Pharmaceutical Contract Research Organization (CRO) | PPD [Internet]. PPD Inc.
 525 [cited 2022 Jun 20]. Available from: https://www.ppd.com
- 526 24. Draize JH. Dermal Toxicity. In: Division of pharmacology food and drug administration
 527 department of health education and welfare, editor. Appraisal of the Safety of Chemicals in
 528 Foods, Drugs, and Cosmetics. Texas: The Association of Food & Drug Officials of the United
 529 States; 1959. p. 46–59.
- 530 25. Montenegro MR, Franco M. Patologia: processos gerais. 4th ed. São Paulo: Atheneu; 2004.
 531 320 p.
- 532 26. Engvall E. The ELISA, Enzyme-Linked Immunosorbent Assay. Clinical Chemistry. 2010 Feb
 533 1;56(2):319–20.
- 27. Brito CF, Fonseca CT, Goes AM, Azevedo V, Simpson AJ, Oliveira SC. Human IgG1 and
 IgG3 recognition of Schistosoma mansoni 14kDa fatty acid-binding recombinant protein.
 Parasite Immunol. 2000 Jan;22(1):41–8.

- 28. Oswaldo Cruz Foundation. Phase 1 Study to Evaluate the Safety of the Vaccine Prepared
 sm14 Against Schistosomiasis [Internet]. clinicaltrials.gov; 2016 Aug [cited 2022 May 10].
 Report No.: NCT01154049. Available from: https://clinicaltrials.gov/ct2/show/NCT01154049
- Food and Drug Administration. FDA. Guidance for industry: toxicity grading scale for healthy
 adult and adolescent volunteers enrolled in preventive vaccine clinical trials [Internet].
 Rockville: Center for Biologics Evaluation and Research; 2007 [cited 2022 Jun 20]. 8 p.
 Available from: https://www.fda.gov/media/73679/download
- S44 30. Clopper CJ, Pearson ES. The Use of Confidence or Fiducial Limits Illustrated in the Case of
 the Binomial. Biometrika. 1934;26(4):404–13.
- Jones TC, Hunt RD, King NW. Patologia veterinária. 6th ed. São Paulo: Manole; 2000. 1424
 p.
- 32. Mouwen, J. M. V. M VD JE. Atlas Colorido de Patologia Veterinária. 2a Ed. Elsevier; 2008.
 158 p.
- 33. Bacha WJ, Bacha LM. Color atlas of veterinary histology. 3rd ed. Philadelphia, PA: Wiley Blackwell; 2012. 356 p.
- 34. Annex 1 WHO guidelines on non clinical evaluation of vaccines [Internet]. [cited 2022 Mar
 9]. Available from: https://www.who.int/publications/m/item/annex1-nonclinical.p31-63
- 35. Oswaldo Cruz Foundation. Safety and Immunogenicity Evaluation of the Vaccine Candidate
 Sm14 Against Schistosomiasis in Senegalese School Children Healthy or Infected With S.
 Mansoni and/or S. Haematobium. A Comparative, Randomized, Controlled, Open-label Trial
 [Internet]. clinicaltrials.gov; 2019 Dec [cited 2022 May 10]. Report No.: NCT03799510.
 Available from: https://clinicaltrials.gov/ct2/show/NCT03799510
- 36. Tendler M, Foundation OC. Safety and Immunogenicity Evaluation of the Vaccine Candidate
 Sm14 in Combination With the Adjuvant Glucopyranosyl Lipid A (GLA-SE) in Adults Living
 in Endemic Regions for S. Mansoni and S. Haematobium in Senegal. A Comparative,
 Randomized, Open-label Trial [Internet]. clinicaltrials.gov; 2017 Dec [cited 2022 May 15].
 Report No.: NCT03041766. Available from: https://clinicaltrials.gov/ct2/show/NCT03041766

Supporting information 565

- S1 Table. Demographic characteristics of the female participants at the baseline. 566
- (DOCX) 567
- 568
- S1 Fig. Flowchart for the phase 1b clinical trial, including enrollment and clinical follow-up 569
- at the Brazilian National Institute of Infectology Evandro Chagas. 570
- (TIF) 571
- 572





* = p-values significant at 0.05 significance level when compared between pre-vaccination (Day 0) and post-vaccination.



